Join experts from GemPharmatech and BioRay Pharmaceutical as they discuss the use of humanized mice to evaluate antibody-drug conjugates for treating autoimmune diseases.
There are currently thirteen FDA-approved Antibody-Drug Conjugates (ADCs) for cancer treatment, and this promising technology is now showing potential in treating autoimmune diseases in humans. However, due to poor cross-species reactivity between therapeutic antibodies and their targets, uncovering the potential of these therapeutics has proven complicated when using conventional mouse models.
In this webinar, Director of Scientific Engagement at GemPharmatech, Dr. Jun Wang, and President of BioRay Pharmaceutical, Dr. Gang Chen, will discuss how humanized mice help overcome the limitations of conventional mouse models and provide insights on how to use these models to evaluate the therapeutic potential of ADCs.
Key Topics Include:
- Advantages of using humanized mouse models to evaluate ADCs
- Applications of humanized mice to evaluate ADCs in autoimmune disease models
- The design and screening of the Linker-Payloads of Bioray’s Immune modulating ADC (ImADCTM)
- Categories: Cell & Molecular Biology, Drug Discovery & Development, Lab Animal Sciences, Microbiology & Immunology
- Tags: antibody-drug conjugates, autoimmune disease, humanized mice
Presenters
Gang Chen, PhD
President
Bioray Pharmaceutical
Jun Wang, PhD
Director of Scientific Engagement
GemPharmatech